期刊论文详细信息
Therapeutic Advances in Medical Oncology 卷:14
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
Meta-analysis
Yingxin Xu1  Florence R. Wilson2  Patricia Guyot3  Chieh-I Chen1  Sam Keeping2  Gerasimos Konidaris4  Keith Chan2  Andreas Kuznik1  Kokuvi Atsou3  Emily Glowienka5  Jean-Francois Pouliot1  Giuseppe Gullo1  Petra Rietschel1 
[1] Sanofi, Reading, UK
[2] Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA
[3] Precision HEOR, Boston, MA, USA
[4] Sanofi, Chilly-Mazarin, France
[5] Precision HEOR, Vancouver, BC, Canada
关键词: cemiplimab;    cemiplimab monotherapy;    IO monotherapy;    network meta-analysis;    non-small-cell lung cancer;    PD-L1 expression;    systematic literature review;   
DOI  :  10.1177/17588359221105024
 received in 2021-11-12, accepted in 2022-05-16,  发布年份 2022
来源: Sage Journals
PDF
【 摘 要 】

Background:For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved, cemiplimab being the most recent. In a phase III trial, cemiplimab demonstrated significantly improved overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced NSCLC and PD-L1 ⩾50%. A systematic literature review and network meta-analysis (NMA) was conducted to identify/compare the efficacy/safety of cemiplimab versus pembrolizumab or other immune-oncology monotherapies from randomized-controlled trials (RCTs) published from January 2010 to November 2020.Methods:Relevant RCTs were identified by searching databases and conference proceedings as per ISPOR, NICE, and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. NMA with time-varying hazard ratios (HRs) was performed for OS and PFS. Analyses were conducted for objective response rate (ORR) and safety/tolerability. Fixed-effect models were used due to limited evidence. Various sensitivity analyses were conducted to validate the base case analyses.Results:The feasibility assessment determined that EMPOWER-Lung 1, KEYNOTE-024, and KEYNOTE-042 trials were eligible. IMpower110 was excluded because an incompatible PD-L1 assay (SP142) was used for patient selection. For first-line advanced NSCLC with PD-L1 ⩾50%, cemiplimab was associated with statistically significant improvements in PFS [HR (95% credible interval [CrI]): 0.65 (0.50–0.86), 1–12 months] and ORR [odds ratio (OR) (95% CrI): 1.64 (1.04–2.62)], and comparable OS [HR (95% CrI): 0.77 (0.54–1.10), 1–12 months] versus pembrolizumab. There was no evidence of differences between cemiplimab and pembrolizumab for Grade 3–5 adverse events (AEs) [OR (95% CrI): 1.47 (0.83–2.60)], immune-mediated AEs [1.75 (0.33–7.49)], and all-cause discontinuation due to AEs [1.21 (0.58–2.61)].Conclusions:Considering the limitations of indirect treatment comparisons, in patients with advanced NSCLC and PD-L1 ⩾50%, cemiplimab monotherapy demonstrated significant improvements in PFS and ORR, comparable OS, and no evidence of differences in safety/tolerability versus pembrolizumab.

【 授权许可】

CC BY   
© The Author(s), 2022

【 预 览 】
附件列表
Files Size Format View
RO202609140011611ZK.pdf 762KB PDF download
RO202609140000501ZK.pdf 7541KB PDF download
Figure 9 45KB Image download
Figure 13 56KB Image download
Figure 2 95KB Image download
Figure 14 24KB Image download
【 图 表 】

Figure 14

Figure 2

Figure 13

Figure 9

【 参考文献 】
  • [1]
  • [2]
  • [3]
  • [4]
  • [5]
  • [6]
  • [7]
  • [8]
  • [9]
  • [10]
  • [11]
  • [12]
  • [13]
  • [14]
  • [15]
  • [16]
  • [17]
  • [18]
  • [19]
  • [20]
  • [21]
  • [22]
  • [23]
  • [24]
  • [25]
  • [26]
  • [27]
  • [28]
  • [29]
  • [30]
  • [31]
  • [32]
  • [33]
  • [34]
  • [35]
  • [36]
  • [37]
  • [38]
  • [39]
  • [40]
  • [41]
  • [42]
  • [43]
  • [44]
  • [45]
  • [46]
  • [47]
  • [48]
  • [49]
  • [50]
  • [51]
  • [52]
  • [53]
  • [54]
  • [55]
  • [56]
  • [57]
  • [58]
  • [59]
  • [60]
  • [61]
  • [62]
  • [63]
  • [64]
  • [65]
  • [66]
  • [67]
  • [68]
  • [69]
  • [70]
  • [71]
  • [72]
  • [73]
  • [74]
  • [75]
  • [76]
  • [77]
  • [78]
  • [79]
  • [80]
  • [81]
  • [82]
  • [83]
  • [84]
  • [85]
  文献评价指标  
  下载次数:0次 浏览次数:0次